STERLING ADDS DRY LASER IMAGERS VIA POLAROID PACT; LOWER COST IMAGERS BASED ON POLAROID'S HELIOS TECHNOLOGY TO BE LAUNCHED IN U.S. IN 1997
This article was originally published in The Gray Sheet
Executive Summary
Sterling Diagnostic Imaging plans to begin marketing low- and mid-range dry laser imagers in the U.S. in 1997 under a collaborative agreement with Polaroid, the companies said during an Oct. 30 teleconference. The two firms announced a long-term, exclusive product development agreement under which Polaroid's Medical Imaging Systems group will develop lower priced imagers based on technology in its high-end Helios 810 and Helios 1417 dry laser imaging systems.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.